Wits University trial Covid-19 vaccine only 49.4% effective
The University of the Witwatersrand (Wits University) has clarified earlier statements about the apparent effectiveness of its experimental Covid-19 vaccine.
This comes after the university announced on Thursday 28 January that the Novavax Covid-19 vaccine trial in South Africa indicated it was effective against the new Covid-19 variant.
“The Novavax vaccine, known as NVX-CoV2373, is the first vaccine to demonstrate not only high clinical efficacy against the prototype SARS-CoV-2, but also significant clinical efficacy against both the rapidly emerging South African (501Y.V2 variant) and UK mutant (N501Y) variants,” the University said.
Update: At 12:15am this morning Wits issued a clarification on this: The #Novovax #COVID19vaccine was 60% effective in HIV- . The jab worked less well in HIV+ ppl. When scientists combined the results for the 2 groups, the OVERALL effectiveness of the jab went down to 49.4%.
— Laura Lopez Gonzalez (@LLopezGonzalez) January 29, 2021
But media reports confused the efficacy trial percentage with an overall effectiveness. Wits has now clarified the initial comments saying the Novovax vaccine was 60% effective in combating HIV. It was, however, not as effective fighting the Covid-19 virus, slipping to 50% in trials.
When scientists combined the results for the two groups of test subjects, the overall effectiveness of the jab went down to 49.4%.
Efficacy against the variant
The vaccine is being tested in both South Africa and the United Kingdom.
“The higher efficacy of the vaccine in the UK than in South Africa is because the variants circulating in SA are less sensitive to vaccine induced immune responses,” said Professor Shabir Madhi, head of the university’s Vaccines and Infectious Diseases Analytics research unit (VIDA).
(1/2) The Novavax vaccine is the first vaccine to demonstrate not only high clinical efficacy against the prototype SARS-CoV-2, but also significant clinical efficacy against both the rapidly emerging South African and UK mutant variants. Learn more: https://t.co/sbaw3KMJpd pic.twitter.com/vRMeNlvaFQ
— Wits University (@WitsUniversity) January 28, 2021
“Nevertheless, the 60% reduced risk against Covid-19 illness in vaccinated individuals in South Africans underscores the value of this vaccine to prevent illness from the highly worrisome variant currently circulating in South Africa, and which is spreading globally,” he said.
“The public health value of vaccines extends beyond a simple point estimate. The ability of Covid-19 vaccines to impact the pandemic will depend on the product, its efficacy, and how quickly we can scale up coverage of the vaccine eventually,” Madhi explained.
Ongoing trials
In December, scientists discovered a new variant of the coronavirus, with lineages that may respond differently to existing vaccines. Wits said it plans to select ideal candidates for a booster and a possible combination bivalent vaccine to test against the new variant in the next few days.
As part of the second phase of trials, South Africa will enrol up to 2,904 volunteers between the ages of 18 and 64. The aim is to test the vaccine’s safety and effectiveness against the existing Covid-19 strain and the new variant.
The company plans to initiate clinical testing of these new vaccines in the second quarter of this year. But there are positive signs for production of the vaccine according to Novavax President of Research and Development, Gregory M Glenn.
“Combined with the safety profile that has been observed in our studies to-date with our Covid-19 vaccine, as well as prior studies in influenza, we are optimistic about our ability to rapidly adapt to evolving conditions,” he said.
The Novavax trial is part of the Coalition for Epidemic Preparedness Innovations (CEPI), which has funded manufacturing of doses and the cost of clinical trials. CEPI is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation.—Health-e News
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Wits University trial Covid-19 vaccine only 49.4% effective
by Des, Health-e News
January 29, 2021
Related
#Budget2021: Government allocates R10bn for vaccines
Finance Minister Tito Mboweni has announced that government is allocating more than R10 billion for the purchase and delivery of vaccines over the next two years.
Two variants of the coronavirus have combined to form ‘Frankenvirus’ – report
An investigation by scientists in the United States revealed two variants of the coronavirus have combined to create a ‘heavily mutated hybrid.’
#Covid-19: AstraZeneca vaccine rollout halted in South Africa
South Africa’s government has decided to stop the planned rollout of the AstraZeneca Covid-19 vacccine after clinical trials found it is not as effective as hoped against the new variant reported in the country.